Abstract

Objective: To compare the efficacy and compliance of the conventional therapy of iron deficiency anemia (ferrous sulfate) with the new forms of therapy chewable iron tablets: (iron polymaltose complex) in the treatment of iron deficiency anemia in pregnant women. Methods: This Randomized Control Trial study included 290 pregnant women with iron deficiency anemia, and they were randomly allocated to a control group who received ferrous sulfate capsules for two months and study group who received iron polymaltose complex chewable tablets for two months. Complete Blood Picture (hemoglobin level and hematocrit level) and Serum ferritin level were done after four and eight weeks to determine the efficacy. In addition, any complains or side effects had been reported to assess the tolerability of the drugs. Two-factor repeated-measures analysis of variance (ANOVA) was used to compare the change in hemoglobin and serum ferritin levels in both groups. Results: There was no statistical significant difference between the two research groups as regards baseline hemoglobin, and at week 4 from onset of treatment (p values = 0.990, 0.112, consecutively). However, there was statistical significant difference on week 8 of continuous drug intake in both groups in which the iron poly maltose complex research group had significantly higher hemoglobin levels (p value = 0.006). Conclusion: The results of the study showed oral iron polymaltose complex increases Hemoglobin and serum ferritin levels more than oral ferrous sulfate and produces less adverse effects than ferrous sulfate.

Highlights

  • The World Health Organization (WHO) defines anemia in pregnancy as a hemoglobin (Hb) concentration of < 11 g/dl

  • To compare the efficacy and compliance of the conventional therapy of iron deficiency anemia with the new forms of therapy chewable iron tablets: in the treatment of iron deficiency anemia in pregnant women. This Randomized Control Trial study included 290 pregnant women with iron deficiency anemia, and they were randomly allocated to a control group who received ferrous sulfate capsules for two months and study group who received iron polymaltose complex chewable tablets for two months

  • This study was conducted on 290 pregnant women with iron deficiency anemia: Ferrous sulfate group mean age of 31.8 ± 5.8 and Iron polymaltose complex group 31.3 ± 5.4

Read more

Summary

Introduction

The World Health Organization (WHO) defines anemia in pregnancy as a hemoglobin (Hb) concentration of < 11 g/dl. Iron deficiency anemia is the most common type of anemia in pregnancy. The WHO estimates that 58% of pregnant women in developing countries are anemic mainly because of iron deficiency [2]. Almost all cases of iron deficiency anemia respond readily to treatment with iron supplementation, patients do not always respond adequately to oral iron therapy because of noncompliance due to side effects. Gastrointestinal disturbances characterized by colicky pain, nausea, vomiting, diarrhea, and gastric distress occur in about 6% - 12% of patients taking iron preparations [3]. The most common iron salt used for oral administration is ferrous sulfate, it is known to produce intestinal side effects (nausea, vomiting, constipation, bloating) in many users [4]. Iron Polymaltose Complex (IPC), a combination of ferric iron with maltol (a food additive), was developed as a molecule that is soluble at neutral pH and is not chelated by other substances [5]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call